Mitral Regurgitation Chronic: Difference between revisions
No edit summary |
m (Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +)) |
||
| (5 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
{{CMG}} | {{CMG}} | ||
'''Associate Editor-In-Chief:''' {{CZ}} | '''Associate Editor-In-Chief:''' {{CZ}}; [[Varun Kumar]], M.B.B.S.; [[Lakshmi Gopalakrishnan]], M.B.B.S. | ||
Individuals with chronic mitral regurgitation can be treated with vasodilators as well. In the chronic state, the most commonly used agents are [[ACE inhibitor]]s and [[hydralazine]]. Studies have shown that the use of ACE inhibitors and hydralazine can delay surgical treatment of mitral regurgitation<sup>1,2</sup>. The current guidelines for treatment of mitral regurgitation limit the use of vasodilators to individuals with [[hypertension]] | Individuals with chronic mitral regurgitation can be treated with vasodilators as well. In the chronic state, the most commonly used agents are [[ACE inhibitor]]s and [[hydralazine]]. Studies have shown that the use of ACE inhibitors and hydralazine can delay surgical treatment of mitral regurgitation<sup>1,2</sup>. The current guidelines for treatment of mitral regurgitation limit the use of vasodilators to individuals with [[hypertension]] | ||
There are two surgical options for the treatment of mitral regurgitation: mitral valve replacement and mitral valve repair. | There are two surgical options for the treatment of mitral regurgitation: mitral valve replacement and mitral valve repair. | ||
===[[MR | ===[[MR ACC/AHA guidelines for management|ACC/AHA guidelines for management]]=== | ||
==References== | |||
===[ | 1. Greenberg BH, Massie BM, Brundage BH, Botvinick EH, Parmley WW, Chatterjee K. Beneficial effects of hydralazine in severe mitral regurgitation. Circulation. 1978 Aug;58(2):273-9. ([http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=668075 Medline abstract]) | ||
2. Hoit BD. Medical treatment of valvular heart disease. Curr Opin Cardiol. 1991 Apr;6(2):207-11. ([http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=10149580 Medline abstract]) | |||
Latest revision as of 17:28, 9 August 2012
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]; Varun Kumar, M.B.B.S.; Lakshmi Gopalakrishnan, M.B.B.S.
Individuals with chronic mitral regurgitation can be treated with vasodilators as well. In the chronic state, the most commonly used agents are ACE inhibitors and hydralazine. Studies have shown that the use of ACE inhibitors and hydralazine can delay surgical treatment of mitral regurgitation1,2. The current guidelines for treatment of mitral regurgitation limit the use of vasodilators to individuals with hypertension
There are two surgical options for the treatment of mitral regurgitation: mitral valve replacement and mitral valve repair.
ACC/AHA guidelines for management
References
1. Greenberg BH, Massie BM, Brundage BH, Botvinick EH, Parmley WW, Chatterjee K. Beneficial effects of hydralazine in severe mitral regurgitation. Circulation. 1978 Aug;58(2):273-9. (Medline abstract)
2. Hoit BD. Medical treatment of valvular heart disease. Curr Opin Cardiol. 1991 Apr;6(2):207-11. (Medline abstract)